9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 300

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Overall Survival,  Survival rate,  Progression Free Survival, Best response

Interventions: rAd-IFN, Celecoxib Oral Product

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: November 2023

Completion Date: November 2024

Last  Posted Date: July 31, 2019

Location: University of California, Los Angeles (UCLA) – Medical Center, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03710876

Was this article helpful?
Dislike 0